A recent editorial in Nature Nanotechnology discusses the enormous feat of scientific innovation, with messenger RNA (mRNA)-based vaccines developed to deliver the gene sequence of specific SARS-CoV-2 viral proteins into host cells using nanotechnology platforms. This new class of genetic-based vaccine is unlike traditional vaccine models, which typically administer entire viruses – either as attenuated live viruses, inactivated viruses, or engineered viruses that closely resemble the targeted pathogen, to elicit the desired immune response.

 

 

BlackJack3D/iStock

Read more…